Day: March 22, 2024

Ended 2023 with cash and cash equivalents of $18.9 million Generated positive cash flow from operations of $2.7 million in 2023 OLD GREENWICH, Conn., March 22, 2024 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) (“Star Equity” or the “Company”), a diversified holding company, reported today its financial results for the fourth quarter (Q4) and fiscal year (FY) ended December 31, 2023. All 2023 and 2022 amounts in this release are unaudited. Following the sale of our Digirad Health business on May 4, 2023, all financial results for the 2023 and 2022 reporting periods, unless stated otherwise, relate to continuing operations, which currently include two divisions: Construction and Investments. Q4 2023 Financial Highlights vs. Q4 2022 (unaudited)Revenues decreased by 19.8% to $14.1 million from $17.6 million. Gross...

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “We continue to work closely with our third-party contract manufacturing organization to expeditiously resolve the deficiencies noted in the complete response letter (“CRL”) we received last December, and are targeting a Biologics License Application (“BLA”) resubmission for cosibelimab by mid-year to potentially obtain marketing approval before the end of 2024. Simultaneously, we continue to execute on a select number of key long lead time commercial launch preparation activities...

– Q4 Revenue Increased 89% Sequentially to a Record $9.5 Million, Driven by Ongoing Customer Demand Strength – – Revenue for the Full Year 2023 Increased to $16.1 Million Compared to $428.1k in 2022 – IRVING, Texas, March 22, 2024 (GLOBE NEWSWIRE) — Sow Good Inc. (OTCQB: SOWG) (“Sow Good” or “the Company”), a trailblazer in the freeze dried candy and treat industry, is reporting financial and operating results for the fourth quarter and full year ended December 31, 2023. “Our strong 2023 results reflect our swift momentum and progress as a first mover in the freeze dried candy space,” said Claudia Goldfarb, CEO of Sow Good. “We achieved fourth quarter revenue of $9.5 million, marking a new quarterly record and an 89% sequential increase relative to the third quarter of 2023. Customer demand for our products...

-Biologics License Application (BLA) for HAV™ Accepted by FDA on February 8, 2024- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024- -Raised approximately $43.1 million in net proceeds from public offering of common stock- -Conference call and live webcast at 8:00 a.m. ET today- DURHAM, N.C., March 22, 2024 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced financial results for the fourth quarter and year ended December 31, 2023 and highlighted recent corporate accomplishments in advancing the investigational Human Acellular Vessel (HAV) closer to planned U.S. market launch. “During 2023, we accomplished major goals across all of...

Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line settingExpect updated Phase 2 data with additional patients in Q2 2024; Company will also provide pivotal trial design and development strategyFinalizing Investigational New Drug (IND)-enabling activities for HB-700 for treatment of KRAS mutated cancersIND submission is on track for filing by April 2024, which would trigger a milestone payment from collaboration partnerGilead-partnered infectious disease programs progressing on scheduleIND clearance achieved for HB-500 for treatment of HIV in Q4 2023; Clinical trial on track to start in Q2 2024, first patient dosed includes associated milestone paymentStrong cash position at year end 2023 of $117.5 million...

TEL AVIV, Israel, March 22, 2024 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace company focused on drone technologies for commercial drones, defense drones, and urban air mobility aircraft, reported today its financial results for year ended December 31, 2023. Key Highlights of ParaZero’s Achievements in 2023 & Recent Highlights:ParaZero announced a new development agreement with Colombia-based drone OEM, Black Square, an industrial drone producer leader in the region that focuses on enterprise drone platforms.ParaZero announced the formation of a working partnership with KULR Technology Group, Inc., a global leader in sustainable energy management, to leverage its business network within the defense industry for applying KULR’s vibration reduction...

Q4 2023 revenues were a record $7.0 million, up 27% from Q4 2022 FY 2023 revenues were a record $20.4 million, up 22% from FY2022 Operating income was $1 million for Q4 2023 compared to an operating loss of $1.5 million for Q4 2022 Company provides guidance for revenue growth of 45-55% for Q1 2024 vs Q1 2023 and initiates annual guidance for FY2024 of 50% revenue growth vs. FY2023 EDEN PRAIRIE, MN, March 22, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months and fiscal year ended December 31, 2023. Q4 2023 ended December 31, 2023Revenue for the three months ended December 31, 2023 totaled $7.0 million, an increase...